Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revacept - AdvanceCor

Next Previous
Drug Profile

Revacept - AdvanceCor

Alternative Names: Dimeric glycoprotein VI-Fc; GPVI-Fc; PR-15; Revacept

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corimmun
  • Developer advanceCor
  • Class Antiarrhythmics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Heart failure therapies; Imaging agents; Platelet membrane glycoproteins; Recombinant fusion proteins; Vascular disorder therapies
  • Mechanism of Action Platelet membrane glycoprotein VI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Coronary artery disease; Stroke
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 04 Apr 2024 Phase-I clinical trials in Peripheral arterial disorders (IV), prior to April 2024 (AdvanceCor pipeline, April 2024)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Acute coronary syndromes(Diagnosis) in Germany (IV, Injection)
  • 16 Apr 2021 Revacept is still in phase II trials for Coronary artery disease in Germany (NCT03312855)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top